J M Kolesar

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. pmc A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)
    Daniel R Greenwald
    Stanford University, Stanford, CA, USA
    J Hematol Oncol 6:46. 2013
  2. doi request reprint Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes
    Jill M Kolesar
    University of Wisconsin Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 554 CSC, Madison, WI, 53792, USA
    Cancer Chemother Pharmacol 72:661-7. 2013
  3. pmc The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer
    Jill M Kolesar
    School of Pharmacy, University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI 53792 5669, USA
    Oncol Rep 25:1765-72. 2011
  4. pmc A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers
    Jill M Kolesar
    University of Wisconsin, Madison, WI 53792, USA
    Cancer Prev Res (Phila) 3:1565-70. 2010
  5. pmc Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients
    Jill Kolesar
    Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, 600 Highland Avenue, K4 554, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 67:393-400. 2011
  6. ncbi request reprint Direct quantification of AD-36 adenovirus DNA by capillary electrophoresis with laser-induced fluorescence
    J M Kolesar
    School of Pharmacy, University of Wisconsin, Madison 53706, USA
    J Chromatogr B Biomed Sci Appl 744:1-8. 2000
  7. pmc Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors
    Jill Kolesar
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:79-86. 2009
  8. pmc Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine
    Jill M Kolesar
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Madison, 600 Highland Avenue, Room K4 554, Madison, WI 53792, USA
    J Inorg Biochem 102:693-8. 2008
  9. ncbi request reprint Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue
    Jill M Kolesar
    School of Pharmacy, University of Wisconsin Madison, 777 Highland Avenue, Madison, WI 53706 1515, USA
    Int J Oncol 21:1119-24. 2002
  10. pmc The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
    Brian S Choi
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI, 53792, USA
    Cancer Chemother Pharmacol 66:973-80. 2010

Collaborators

Detail Information

Publications29

  1. pmc A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)
    Daniel R Greenwald
    Stanford University, Stanford, CA, USA
    J Hematol Oncol 6:46. 2013
    ..Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL. ..
  2. doi request reprint Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes
    Jill M Kolesar
    University of Wisconsin Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 554 CSC, Madison, WI, 53792, USA
    Cancer Chemother Pharmacol 72:661-7. 2013
    ..Vorinostat is a small molecule inhibitor of class I and II histone deacetylase enzymes which alters the expression of target genes including the cell cycle gene p21, leading to cell cycle arrest and apoptosis...
  3. pmc The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer
    Jill M Kolesar
    School of Pharmacy, University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI 53792 5669, USA
    Oncol Rep 25:1765-72. 2011
    ..Although the basis for the NQO1 association with decreased survival requires additional evaluation, NQO1 may represent a biomarker for guiding individualized therapy...
  4. pmc A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers
    Jill M Kolesar
    University of Wisconsin, Madison, WI 53792, USA
    Cancer Prev Res (Phila) 3:1565-70. 2010
    ..018 to 0.103 L/h. 9cUAB30 has a favorable toxicity and pharmacokinetic profile, with oral availability and primarily hepatic metabolism. Further dose ranging studies with once a day dosing are underway...
  5. pmc Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients
    Jill Kolesar
    Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, 600 Highland Avenue, K4 554, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 67:393-400. 2011
    ....
  6. ncbi request reprint Direct quantification of AD-36 adenovirus DNA by capillary electrophoresis with laser-induced fluorescence
    J M Kolesar
    School of Pharmacy, University of Wisconsin, Madison 53706, USA
    J Chromatogr B Biomed Sci Appl 744:1-8. 2000
    ..These results indicate that direct detection with capillary electrophoresis with laser-induced fluorescence (CE-LIF) is a reliable and sensitive method for quantifying AD-36 viral DNA...
  7. pmc Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors
    Jill Kolesar
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:79-86. 2009
    ..The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP...
  8. pmc Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine
    Jill M Kolesar
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Madison, 600 Highland Avenue, Room K4 554, Madison, WI 53792, USA
    J Inorg Biochem 102:693-8. 2008
    ..A potential source for the increase in the heme signal is cytochrome c released from the mitochondria. These results provide valuable insight into the in vivo mechanism of action of Triapine...
  9. ncbi request reprint Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue
    Jill M Kolesar
    School of Pharmacy, University of Wisconsin Madison, 777 Highland Avenue, Madison, WI 53706 1515, USA
    Int J Oncol 21:1119-24. 2002
    ..007), suggesting NQO1 may be important in chemosensitivity as well as the pathogenesis of lung cancer and NQO1 genotyping may be a useful component of pharmacogenetic strategies for the treatment of NSCLC...
  10. pmc The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
    Brian S Choi
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI, 53792, USA
    Cancer Chemother Pharmacol 66:973-80. 2010
    ..This study was conducted to determine the toxicity and antitumor activity of 3-AP with irinotecan. Correlative studies included pharmacokinetics and the effects of ABCB1 and UGT1A1 polymorphisms...
  11. pmc A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors
    William R Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K6 568, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 63:1147-56. 2009
    ..To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics and antitumor activity of Triapine administered in combination with doxorubicin...
  12. pmc A Bayesian adaptive design with biomarkers for targeted therapies
    Jens C Eickhoff
    Department of Biostatistics and Medical Informatics, University of Wisconsin Madison, Madison, WI, USA
    Clin Trials 7:546-56. 2010
    ..In traditional clinical trials, treatment effects for various biomarkers are typically evaluated in an exploratory fashion and only limited information about the predictive values of biomarkers obtained...
  13. pmc Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States
    Lung Cancer 64:51-9. 2009
    ..The safety and tolerability of combination therapy with the EGFR inhibitor, gefitinib, and fulvestrant was explored...
  14. pmc A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, K6 568 CSC, 5669, 600 Highland Avenue, Madison, WI, 53792, USA
    Invest New Drugs 28:91-7. 2010
    ..The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC...
  15. ncbi request reprint Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer
    Lindsey Wilhelm
    Pharmacy Practice Division, School of Pharmacy, University of Wisconsin, Madison 53705, USA
    Am J Health Syst Pharm 62:1365-9. 2005
    ..The role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) is described...
  16. pmc Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    J Thorac Oncol 4:522-6. 2009
    ..Vorinostat is a small molecule inhibitor of histone deacetylase, and has shown preclinical activity in non-small cell lung cancer (NSCLC)...
  17. ncbi request reprint Role of trastuzumab in adjuvant therapy for locally invasive breast cancer
    Katie L Kabe
    School of Pharmacy, University of Wisconsin, Madison, WI 53719, USA
    Am J Health Syst Pharm 63:527-33. 2006
    ..The role of trastuzumab in adjuvant therapy for locally invasive breast cancer is discussed...
  18. ncbi request reprint Pharmacogenetics and irinotecan therapy
    Kristine K Hahn
    University of Wisconsin Comprehensive Cancer Center UWCCC, Madison, WI 53705, USA
    Am J Health Syst Pharm 63:2211-7. 2006
    ..Irinotecan metabolism, irinotecan pharmacogenetic research, and the role of genetic testing before administration of the drug are reviewed...
  19. doi request reprint Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma
    Jon J Hiles
    School of Pharmacy, University of Wisconsin, Madison, WI 53705, USA
    Am J Health Syst Pharm 65:123-31. 2008
    ..The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed...
  20. ncbi request reprint Gene-expression assays: new tools to individualize treatment of early-stage breast cancer
    Elizabeth Dobbe
    School of Pharmacy, University of Wisconsin, Madison, WI 53705 2222, USA
    Am J Health Syst Pharm 65:23-8. 2008
    ..The clinical and economic data for the two currently available gene-expression assays are reviewed...
  21. ncbi request reprint Assessing therapeutically developed assays
    Jill M Kolesar
    Analytical Instrumentation Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics, University of Wisconsin, Paul P Carbone Comprehensive Cancer Center, Madison, USA
    Manag Care 17:9-12; discussion 17-8. 2008
    ..Economic analyses suggest that appropriate use of clinically validated molecular diagnostics offers the potential for cost savings and improved patient quality of life...
  22. ncbi request reprint Novel approaches to anemia associated with cancer and chemotherapy
    Jill M Kolesar
    School of Pharmacy, University of Wisconsin Madison, William S Middleton Veterans Affairs Hospital, Madison, WI, USA
    Am J Health Syst Pharm 59:S8-11. 2002
    ..No difference in toxicity between the two agents has been reported. Epoetin alfa and darbepoetin alfa are effective in the treatment of anemia in patients with cancer...
  23. doi request reprint Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma
    Shannon M Kavanaugh
    School of Pharmacy, University of Wisconsin, Madison USA
    Am J Health Syst Pharm 67:793-7. 2010
    ..The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects, dosage and administration, and role in therapy of vorinostat in the treatment of cutaneous T-cell lymphoma (CTCL) are reviewed...
  24. doi request reprint Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer
    Amye J Tevaarwerk
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
    Clin Ther 31:2332-48. 2009
    ..In March 2007, the US Food and Drug Administration approved lapatinib for use in combination with capecitabine in the treatment of advanced breast cancer overexpressing HER2 (HER2+)...
  25. doi request reprint Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma
    Trevor W Dennie
    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
    Clin Ther 31:2290-311. 2009
    ....
  26. doi request reprint Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors
    Erin E Mancl
    School of Pharmacy, University of Wisconsin UW, Madison, USA
    Am J Health Syst Pharm 66:2105-12. 2009
    ..The clinical and economic value of screening for Kras mutations as predictors of response to cetuximab and panitumumab are reviewed...
  27. doi request reprint Hydroxyurea induced acute elevations in liver function tests
    Mike J Hallam
    University of Wisconsin, School of Pharmacy, Madison, WI 53792, USA
    J Oncol Pharm Pract 14:61-3. 2008
    ..Patients being initiated on HU should be advised that rarely, fevers, chills, nausea, and elevations in liver function tests may occur...
  28. ncbi request reprint Mitomycin as a modulator of irinotecan anticancer activity
    Miguel A Villalona-Calero
    Department of Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, USA
    Oncology (Williston Park) 16:21-5. 2002
    ..Based on these encouraging phase I data, phase II clinical trials in breast and esophageal/gastroesophageal junction adenocarcinomas at the recommended doses and schedule are under way...
  29. ncbi request reprint EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer
    Sarita Dubey
    University of California, San Francisco, San Francisco, California 94115, USA
    J Thorac Oncol 1:406-12. 2006
    ..The authors hypothesized that a shorter length of tumor SSR would be associated with poorer survival in patients with non-small cell lung cancer (NSCLC)...